Coronavirus Outbreak: USFDA approves albuterol sulfate-based inhaler as demand increases due to COVID-19 pandemic
The generic version of the inhaler will be manufactured by Indian drugmaker Cipla Ltd.
The US Food and Drug Administration (USFDA) has given its nod to the first generic of a commonly used albuterol sulfate-based inhaler.
The demand for albuterol products has seen a spike as people infected with novel coronavirus suffer from breathing difficulties.
“The FDA recognizes the increased demand for albuterol products during the novel coronavirus pandemic,” said FDA Commissioner Stephen Hahn. He added that they are committed to providing medical products to cater to the needs of the public.
The generic version of the inhaler will be manufactured by Indian drugmaker Cipla Ltd. The albuterol sulfate-based inhaler is used in the treatment of bronchospasm, a condition in which patients face difficulty in breathing.
Last month, the drug regulator had put out a revised draft for proposed generic albuterol sulfate metered dose inhalers.
In its press release, USFDA also highlighted the common side-effects associated with albuterol inhalers.
Upper respiratory tract infection, rhinitis, nausea, vomiting, rapid heart rate (tachycardia), tremor and nervousness are the most common side-effects, it said.
The novel coronavirus has infected lakhs of people globally and claimed the lives of thousands. It has also brought financial activities across the world to a grinding halt.
The symptoms of coronavirus infection include fever, coughing and breathing difficulties.
COVID-19 vaccine production increasing, India may be first country to have DNA-based jab, Mansukh Mandaviya tells RS
Replying to a short discussion on COVID-19 management in Rajya Sabha, the minister said technology transfer to several companies has started and they will begin production in the coming days
Centre and states should work as team to combat COVID pandemic, rise above politics, says PM Modi at all-party meet
A number of Opposition parties including the Trinamool Congress, NCP and Samajwadi Party attended the meet, while the main Opposition party Congress skipped it
The travel restriction, imposed by the National Command and Operation Centre (NCOC), will be applicable from 1 August on unvaccinated people of over 18 years of age